MIG Capital’s AbbVie ABBV Stock Holding History

MIG Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,263	Closed	-$302K	–	40
2018 Q2	$302K	Buy	+3,263	New	+$319K	0.04%	25

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

MIG Capital's ABBV Position: Q3 2018 in Review

MIG Capital sold out of AbbVie (ABBV) in Q3 2018, closing a stake of 3,263 shares — an estimated $302K sold.

MIG Capital first reported a position in ABBV in Q2 2018 and held it in 1 quarter. The position peaked at $302K in Q2 2018. 1,957 funds tracked by Wall St. Rank hold ABBV as of Q3 2018.

MIG Capital reported no remaining AbbVie position as of Q3 2018 after selling out during the quarter.
MIG Capital sold 3,263 AbbVie shares in Q3 2018, an estimated $302K.
MIG Capital first reported a position in AbbVie in Q2 2018 and held it in 1 quarter.
MIG Capital's AbbVie position peaked at $302K in Q2 2018.
1,957 funds tracked by Wall St. Rank held AbbVie as of Q3 2018.

Based on MIG Capital's 13F filing for Q3 2018, filed 14 Nov 2018.